Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana F Best

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Lancet (London, England)|January 30, 2017
Trends in premature mortality in the USA by sex, race, and ethnicity from 1999 to 2014: an analysis of death certificate dataMeredith S Shiels, Pavel Chernyavskiy, William F Anderson, et al.
Rhinology Online|June 24, 2021
Nasal chondromesenchymal hamartomas in a cohort with pathogenic germline variation in <i>DICER1</i>Lauren M Vasta, Alison Nichols, Laura A Harney, et al.
JAMA Pediatrics|October 5, 2018
Infant and Youth Mortality Trends by Race/Ethnicity and Cause of Death in the United StatesSahar Q Khan, Amy Berrington de Gonzalez, Ana F Best, et al.
The Lancet. Public Health|January 19, 2019
Premature mortality from all causes and drug poisonings in the USA according to socioeconomic status and rurality: an analysis of death certificate data by county from 2000-15Meredith S Shiels, Amy Berrington de González, Ana F Best, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2019
Neoplasm Risk Among Individuals With a Pathogenic Germline Variant in DICER1Douglas R Stewart, Ana F Best, Gretchen M Williams, et al.
Thorax|March 20, 2024
Prevalence of lung cysts in adolescents and adults with a germline <i>DICER1</i> pathogenic/likely pathogenic variant: a report from the National Institutes of Health and International Pleuropulmonary Blastoma/<i>DICER1</i> RegistryAlexander T Nelson, Lauren M Vasta, Dave Watson, et al.
JAMA Network Open|February 25, 2021
A Genome-First Approach to Characterize DICER1 Pathogenic Variant Prevalence, Penetrance, and PhenotypeUyenlinh L Mirshahi, Jung Kim, Ana F Best, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2021
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0Sara M Tolaney, Elizabeth Garrett-Mayer, Julia White, et al.
JAMA Oncology|July 17, 2025
Risk Factors for COVID-19-Related Hospitalization and Death in Patients With Cancer: The National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS)Brian I Rini, Ana F Best, Mel D Bowman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2023
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEPJennifer K Litton, Meredith M Regan, Lajos Pusztai, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Lancet (London, England)|January 30, 2017
Trends in premature mortality in the USA by sex, race, and ethnicity from 1999 to 2014: an analysis of death certificate dataMeredith S Shiels, Pavel Chernyavskiy, William F Anderson, et al.
Rhinology Online|June 24, 2021
Nasal chondromesenchymal hamartomas in a cohort with pathogenic germline variation in <i>DICER1</i>Lauren M Vasta, Alison Nichols, Laura A Harney, et al.
JAMA Pediatrics|October 5, 2018
Infant and Youth Mortality Trends by Race/Ethnicity and Cause of Death in the United StatesSahar Q Khan, Amy Berrington de Gonzalez, Ana F Best, et al.
The Lancet. Public Health|January 19, 2019
Premature mortality from all causes and drug poisonings in the USA according to socioeconomic status and rurality: an analysis of death certificate data by county from 2000-15Meredith S Shiels, Amy Berrington de González, Ana F Best, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2019
Neoplasm Risk Among Individuals With a Pathogenic Germline Variant in DICER1Douglas R Stewart, Ana F Best, Gretchen M Williams, et al.
Thorax|March 20, 2024
Prevalence of lung cysts in adolescents and adults with a germline <i>DICER1</i> pathogenic/likely pathogenic variant: a report from the National Institutes of Health and International Pleuropulmonary Blastoma/<i>DICER1</i> RegistryAlexander T Nelson, Lauren M Vasta, Dave Watson, et al.
JAMA Network Open|February 25, 2021
A Genome-First Approach to Characterize DICER1 Pathogenic Variant Prevalence, Penetrance, and PhenotypeUyenlinh L Mirshahi, Jung Kim, Ana F Best, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2021
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0Sara M Tolaney, Elizabeth Garrett-Mayer, Julia White, et al.
JAMA Oncology|July 17, 2025
Risk Factors for COVID-19-Related Hospitalization and Death in Patients With Cancer: The National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS)Brian I Rini, Ana F Best, Mel D Bowman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2023
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEPJennifer K Litton, Meredith M Regan, Lajos Pusztai, et al.
Pageof 4